HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Conditions:   Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorders;   Chronic Myeloid Leukemia;   Myelofibrosis;   Multiple Myeloma;   Malignant Lymphoma Interventions:   Drug: MDG1021 dose 1;   Drug: MDG1021 dose 2;   Drug: MDG1021 dose 3;   Drug: MDG1021 optimal dose Sponsor:   Medigene AG Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials